Modality
Gene Therapy
MOA
JAK1i
Target
AuroraA
Pathway
Checkpoint
MG
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
~Sep 2017
→ ~Dec 2018
NDA/BLA
~Mar 2019
→ ~Jun 2020
Approved
Sep 2020
→ Sep 2030
ApprovedCurrent
NCT05452530
70 pts·MG
2025-08→2026-04·Active
NCT07541719
1,222 pts·MG
2023-10→2030-09·Not yet recruiting
NCT05674204
304 pts·MG
2020-09→2026-01·Completed
1,596 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-01-013mo agoPh3 Readout· MG
2026-04-081w awayPh3 Readout· MG
2030-09-014.4y awayPh3 Readout· MG
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Complet…
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2026-01-01 · 3mo ago
MG
Ph3 Readout
2026-04-08 · 1w away
MG
Ph3 Readout
2030-09-01 · 4.4y away
MG
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05452530 | Approved | MG | Active | 70 | OS |
| NCT07541719 | Approved | MG | Not yet recr... | 1222 | CR |
| NCT05674204 | Approved | MG | Completed | 304 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |